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Mucin 1 (MUC1) is a transmembrane mucin glycoprotein that is over-expressed and aber-
rantly glycosylated in >80% of human pancreatic ductal adenocarcinoma (PDA) and is
associated with poor prognosis.To understand the role of MUC1 in PDA, we have recently
developed two mouse models of spontaneous PDA, one that expresses full-length human
MUC1 transgene (KCM mice) and one that is null for MUC1 (KCKO mice). We have pre-
viously reported that KCM mice express high levels of myeloid derived suppressor cells
(MDSCs) in their tumors and develop highly aggressive PDA. To further understand the
underlying mechanism for high MDSC levels in KCM-tumors, we generated primary cell
lines from KCM and KCKO-tumors. In this study, we report that MDSCs derived using KCM
cells express significantly higher levels of arginase 1 and inducible nitric oxide synthase
(markers associated with immune suppression) and lower levels of CD115 (a marker associ-
ated with maturation of myeloid cells) as compared to KCKO-derived MDSCs. Functionally,
KCM-derived MDSCs secrete significantly higher levels of urea and nitric oxide (NO) when
co-cultured with normal splenic cells as compared to KCKO-derived MDSCs. Data indi-
cates that KCM-derived MDSCs remain immature and are more suppressive as compared
to KCKO-derived MDSCs. This was further corroborated in vivo where MDSCs isolated
from KCM-tumor-bearing mice retained their immature state and were highly suppressive
as compared to MDSCs derived from KCKO-tumor-bearing mice. Finally, we show that KCM
cells secrete significantly higher levels of prostaglandin E2 (PGE2), a COX-2 metabolite and
a known driver of suppressive MDSCs as compared to KCKO cells. Thus, inhibiting PGE2
with a specific COX-2 inhibitor reverses the immunosuppressive and immature phenotype
of KCM-derived MDSCs. This is the first report that clearly suggests a functional role of
pancreatic tumor-associated MUC1 in the development of functional MDSCs.
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INTRODUCTION
Every year, an estimated 270,000 deaths occur worldwide due to
pancreatic cancer (1), and in the US, the 1- and 5-year survival
rates for all stages combined are 25 and 6%, respectively (2).
Therapies that are successful in treating other malignancies are rel-
atively ineffective for pancreatic cancer possibly because cells evade
immune recognition (3). Cancer cells release pro-inflammatory
factors that promote the generation of immune suppressor cells
including myeloid derived suppressor cells (MDSCs) (3). MDSCs
play a prominent role in tumor induced immune suppression
and are one of the major factors limiting the efficacy of immune
therapies (4, 5).
Abbreviations: Arg-1, arginase 1; BM, bone marrow; BMDCs, bone marrow derived
cells; COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide synthase; KCKO, PDA
cell line without MUC1; KCM, PDA cell line expressing MUC1; MDSCs, myeloid
derived suppressor cells; MUC1 (human) Muc1 (murine), Mucin 1; NO, nitric oxide;
PDA, pancreatic ductal adenocarcinomas; PGE2, prostaglandin E2; TCCM, tumor
cell conditioned media; TDSFs, tumor derived soluble factors.
Pancreatic ductal adenocarcinoma (PDA) is the most com-
mon type of pancreatic cancer. MUC1 (CD227), a transmembrane
mucin glycoprotein is aberrantly over-expressed in>80% of PDA.
This suggests a pivotal role for MUC1 in the progression of PDA.
MUC1 plays a role in inflammation (6) and cancer progression
(7) and has recently been identified as the second most targetable
tumor-associated antigen by the National Cancer Institute (8).
Indeed, 64% of the tumors diagnosed every year in the United
States have aberrant MUC1 expression (7). MUC1 regulates mul-
tiple pro-tumor activities including proliferation (9), epithelial to
mesenchymal transition (10), and inhibition of apoptosis (11) in
tumor cells. However, its role in tumor induced immune sup-
pression and specifically in the generation of MDSCs is not well
known.
We were the first to report that in a mouse model of spon-
taneous PDA (12), overexpression of human MUC1 transgene
(PDA.MUC1 mice) significantly enhanced tumor progression
and metastasis and showed increased levels of MDSCs and
T-regulatory cells (Tregs) as well as prostaglandin E2 (PGE2)
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within the developing tumor (13). In contrast, PDA mice that
lacked Muc1 (PDA.Muc1-null mice) had stable disease and the
pre-neoplastic lesions did not progress to invasive adenocarcino-
mas (9, 10). The findings strongly suggest a role for MUC1 in
tumor induced immune suppression; possibly via the generation
of suppressive MDSCs.
Myeloid derived suppressor cells consist of a heterogeneous
population of immature myeloid cell types (14). Generally, these
immature myeloid cells differentiate further into mature gran-
ulocytes, macrophages, and dendritic cells. However, in cancer,
inflammation, trauma, or sepsis, this differentiation process is
halted and the myeloid cells remain restricted to their imma-
ture state (15). Specifically, tumor derived soluble factors (TDSFs)
secreted by tumor cells alter MDSC generation, differentiation,
recruitment, and function. TDSFs skew the differentiation of
hematopoietic stem cells (HSC) partially hindering maturation
of the myeloid lineage (15). In these conditions, MDSCs are
found to accumulate in the BM, spleen, blood, lymph nodes, and
within tumors (16, 17). TDSFs including PGE2 (18, 19), GM-
CSF (20), and IL-10 (21) have been implicated in the induction
of MDSCs. These factors not only lead to MDSC expansion but
also MDSC activation. In addition, MDSCs can be activated by
activated T-cells through the action of activated T-cell products;
IFNγ, TGF-β, IL-4, and IL-13. In mice, MDSCs are character-
ized by the co-expression of Gr1 and CD11b molecules (22) and
can be classified into subsets: monocytic (CD11b+Ly6G−Ly6Chi)
and granulocytic (CD11b+Ly6G+Ly6Clo) (23, 24). MDSCs exert
their suppressive activity via a number of different mecha-
nisms; l-arginine depletion (25), nitric oxide (NO) up regu-
lation (26), generation of reactive oxygen species (ROS) (24),
and other free radicals including reactive nitric oxide species
(RNOS) (27). These mechanisms suppress T-cell proliferation and
T-cell effector function, thereby inhibiting anti-tumor immune
responses.
In the present study, we compared the effects of TDSFs from
PDA cells derived from PDA.Muc1-null mice (KCKO) with PDA
cells derived from PDA.MUC1 (KCM) on MDSC phenotype and
function in vitro and in vivo. We report substantive differences
in the maturation state and suppressive function of the MDSCs
derived in the presence of KCM versus KCKO cells/tumors. We
also determined that KCM cells expressed significantly higher lev-
els of COX-2 and secreted higher amounts of PGE2 as compared
to KCKO cells. Thus, MDSC maturation and function may partly
depend upon whether the PDA is Muc1+ or Muc1-null.
MATERIALS AND METHODS
CELL LINES AND MICE
The KCKO pancreatic cancer cell line was generated from
PDA.Muc1-null tumors and the KCM pancreatic cancer cell line
was generated from PDA.MUC1 tumors (9). The murine fibrob-
last cell lines 3T12 and L929 (ATCC, Manassas, VA, USA), served
as negative controls and B16 murine melanoma cell line (a
gift from Dr. Tony Hollingsworth, University of Nebraska Med-
ical Center) served as the positive control for Gr1+CD11b+
MDSCs. B16.Neo (transfected with neomycin empty vector)
and B16.MUC1 (expressing full-length human MUC1) murine
melanoma cells (a gift from Dr. Tony Hollingsworth, University of
Nebraska Medical Center), served as alternative MUC1 expressing
and MUC1-null cells. All cell lines were maintained in DMEM
(Invitrogen, Grand Island, NY, USA) supplemented with 10% FBS
(HyClone, Logan, UT, USA) and 1% 1× penicillin/streptomycin
(PS; Cellgro, Manassas, VA, USA). All cultures were kept at 37°C
in a 5% CO2 humidified atmosphere.
Mice (6- to 8-week-old C57BL/6, Jackson Laboratory, Bar Har-
bor, Maine, USA) were used for harvesting bone marrows (BM)
and spleens and for generation of pancreatic tumors in vivo. Mice
were handled and maintained in accordance with the University
of North Carolina at Charlotte Institutional Animal Care and Use
Committee (IACUC)-approved protocol.
GENERATION OF CONDITIONED MEDIA
Tumor cells were cultured with DMEM supplemented with
reduced serum (2% FBS). Forty-eight hours post-incubation, the
tumor cell conditioned media (TCCM) containing the TDSFs
released by tumor cells were collected. The TCCMs were cen-
trifuged (3000 rpm, 10 min), filtered (0.2µm filter, Fisher Sci-
entific, Pittsburgh, PA, USA), and stored at −80°C until use.
Fibroblast conditioned media (FCMs) were obtained from 3T12
and L929 fibroblast cells in a similar fashion.
CELECOXIB TREATMENT
KCM cells at 70% confluency were treated with the COX-2
inhibitor Celecoxib (50µM; Pfizer, New York City, NY, USA) in
serum-free DMEM for 48 h. Cells were washed twice with 1× PBS
and incubated for an additional 48 h with fresh DMEM supple-
mented with 2% FBS (reduced serum). TCCMs were collected,
and stored as described above.
PANCREATIC TUMOR GROWTH IN VIVO
1× 106 cells of 3T12, B16.Neo and B16.MUC1, KCKO, and KCM
cells were re-suspended in 100µL of 1× PBS:Matrigel® (BD Bio-
sciences, San Jose, CA, USA) 1:1 and injected subcutaneously into
the flank of C57BL/6 mice. Seventeen days post-injection, the
mice were sacrificed and the tumor and organs harvested. The
tumors were weighed and tumor lysates were prepared. BM and
splenocytes were harvested and used as described below.
GENERATION OF BONE MARROW PROGENITORS
Bone marrow cells were obtained from the femurs and tibias of
6- to 8-week-old C57BL/6 mice. BM cells (1× 106) were cultured
in DMEM supplemented with 10% FBS, 1% PS, 10 ng/ml GM-
CSF (Peprotech, Rocky Hill, NJ, USA), 10 ng/ml IL-4 (Peprotech,
Rocky Hill, NJ, USA), and 50µM of 2-ME alone or in the pres-
ence of 30% v/v TCCM or control (FCM) in 24-well flat bottom
plates as described in Ref. (24, 28, 29). Cells were maintained at
37°C in 5% CO2 humidified atmosphere for 5 days. On day 3 of
culture, floating cells were removed and media replenished with
GM-CSF, IL-4, and TCCM/FCM. As BM cultures are considered
suppressive by day 5 (28), cells were collected on day 5 and analyzed
by flow cytometry. The optimal TCCM concentration (30% v/v)
was determined from titration curves of Gr1+CD11b+MDSCs,
this concentration was not associated with any noticeable BM cell
death. To account for differing proliferation rates between cells
and treatment conditions, BCA analyses were conducted on both
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cell lysates and conditioned media. The total protein concentra-
tions were similar in the lysates and conditioned media obtained
from KCKO, KCM, and KCM cells treated with Celecoxib (data
not shown).
FLOW CYTOMETRY
Floating bone marrow derived cells (BMDC) and loosely adherent
cells from BM cultures were collected, centrifuged, and cell pellet
re-suspended in staining buffer (SB; 1× PBS with 1% FBS and
0.1% sodium azide). Cells were stained with anti-Gr1-APC, anti-
CD11b-PE, anti-Ly6C-FITC, anti-Ly6G-APC, anti-CD11c-FITC,
and biotinylated anti-CD115 for total MDSC population, sub-
sets, and maturation phenotypes, respectively. For the detection
of intracellular antigens, the cells were fixed and simultaneously
permeabilized with BD Cytofix/Cytoperm and stained with anti-
iNOS-FITC and anti-Arg-1 primary antibody and appropriate
secondary APC conjugated antibody. Splenocytes were harvested
from spleens of 6- to 8-week-old C57BL/6 mice under sterile con-
ditions, red blood cells were lysed (1× RBC lysing buffer) and
single-cell suspensions were prepared for staining with anti-Gr1-
APC and anti-CD11b-PE antibodies. KCM and KCKO cells were
made into single-cell suspensions and stained with anti-MUC1-
PE antibody. All antibodies were purchased from BD Biosciences
(BD Biosciences, San Jose, CA, USA). Samples were run on a FAC-
SCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and
data analyzed using the FlowJo software (Tree Star Inc., Ashland,
OR, USA). Data are expressed as percentage positive cells and/or
mean fluorescence intensity (MFI).
BMDCs COLLECTED FOR NITRIC OXIDE AND ARGINASE ACTIVITY
ASSAYS
Bone marrow derived cells were generated as described above with
the following modifications. On day 3, 100 U/ml IFN-γ (Pepro-
tech, Rocky Hill, NJ, USA) and 0.1–1µg/ml LPS (Sigma, St Louis,
MO, USA) were added to enhance the suppressive activity of
MDSCs (30). As MDSCs populations can be sorted by presence
of Gr1 marker alone and are known to possess suppressive activ-
ity on day 5 (31), BMDCs Gr1+cells were sorted using anti-APC
microbeads (Miltenyi, Bergisch Gladbach, Germany) and anti-
Gr1-APC antibody (BD Biosciences, San Jose, CA, USA). The
purity of the sorted cell fraction was >90%.
SPLENOCYTE CO-CULTURE FOR NITRIC OXIDE AND ARGINASE
ACTIVITY ASSAYS
Spleens were harvested from 6- to 8-week-old C57BL/6 mice under
sterile conditions. Red blood cells were lysed (1× RBC lysing
buffer) and single-cell suspensions were prepared. Gr1+ cells iso-
lated from BM cultures were added to 2× 105 naïve C57BL/6
splenocytes per well in 96-well flat bottom plates at 1:1, 1:2, and
1:4 ratios. These co-cultures were stimulated with 1µg/ml anti-
CD3 antibody (BD Biosciences, San Jose, CA, USA). Following a
72-h incubation, supernatants and cell lysates were collected. The
supernatants were assessed for NO production and the cell lysates
were used to determine arginase activity. Gr1+ cells from BM cul-
tures of tumor-bearing mice were incubated with freshly isolated
splenocytes at the optimal ratio of 1:1 for the NO and urea activ-
ity assays. Anti-CD3 antibody was added to stimulate splenocytes
as MDSCs are activated and produce NO and urea only in the
presence of activated/stimulated T-cells.
NITRIC OXIDE PRODUCTION
Equal volumes of culture supernatants were mixed with Griess
reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N -
1-naphthylethylenediamine dihydrochloride in double-distilled
water; Promega, Fitchburg, WI, USA) and incubated at room tem-
perature for 10 min. The absorbance was measured at 550 nm
using a BioTek microplate reader (BioTek, Winooski, VT, USA).
Nitrate concentrations (µM) were determined by comparing sam-
ple OD values to a standard curve generated by serial dilution of
0.1 mM sodium nitrite.
ARGINASE ACTIVITY
Gr1+ cells were lysed for 30 min with 100µl of 0.1% Triton
X-100. Subsequently, 100µl of 25 mM Tris–HCl and 10µl of
10 mM MnCl2 were added. The arginase enzyme was activated
by heating the lysate for 10 min at 56°C. 100µl of 0.5 M l-
arginine (pH 9.7) substrate was added to the lysate and incubated
for 120 min at 37°C. Reaction was stopped with 900µl of acid
mixture 1 H2SO4 (96%):3 H3PO4 (85%):7 H2O. 40µl of α-
isonitrosopropiophenone (dissolved in 100% ethanol) was added
to the mixture and heated for 30 min at 95°C. Absorbance was mea-
sured at 540 nm. The urea concentrations (µM) were determined
by comparing sample OD values to urea standards generated by
serial dilution of 1 mM urea solution.
LYMPHOCYTE PROLIFERATION ASSAY
To monitor lymphocyte proliferation in the presence of Gr1+
MDSCs, single-cell suspensions of splenocytes harvested from 6-
to 8-week-old C57BL/6 mice were stained using the CellTrace
CFSE Cell Proliferation Kit (Molecular Probes, Eugene, OR, USA).
The splenocytes were centrifuged at 2000 rpm for 2 min to obtain
a pellet. The pellet was re-suspended in pre-warmed PBS with
0.1% BSA containing the probe at a final working concentra-
tion of 10µM to a final concentration of 1× 106 cells/ml. Cells
were incubated at 37°C for 15 min, and then pelleted by centrifu-
gation at 2000 rpm for 2 min. Labeled cells were re-suspended
in pre-warmed media, and incubated for 30 min at 37°C. The
cells were then pelleted again by centrifugation and washed twice
before being re-suspended in media supplemented with serum
at the desired concentration. To measure the fluorescence at Day
0, 0.5× 106 cells were kept aside. After 3 days the fluorescence
was determined. CFSE dilution was analyzed using FACSCal-
ibur and further analyzed with the FlowJo software. Data was
expressed in terms of a proliferation index wherein MFI values
of CSFE fluorescence are normalized to Day 0 CFSE fluorescence
of splenocytes.
WESTERN BLOTS AND ELISA
Protein lysates (30µg per sample) were separated by SDS-PAGE
and transferred to PVDF membrane for immunoblotting. Anti-
COX-2, anti-MUC1 TR (extracellular portion of MUC1), anti-
MUC1 CT (cytoplasmic tail of MUC1), and anti-IL-10 antibodies
(SantaCruz Biotechnology, Dallas, TX, USA) were used.
PGE2 ELISAs were performed using the Prostaglandin E2 EIA
Kit-Monoclonal kit (Cayman Chemical; Ann Arbor, MI, USA) on
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TCCM and FCM. PGEM (13,14-dihydro 15-keto PGA2) ELISAs
were performed using the Prostaglandin E Metabolite EIA Kit
(Cayman Chemical; Ann Arbor, MI, USA) on tumor lysates and
serum from tumor-bearing mice. PGE2 is metabolized rapidly
in vivo and hence an accurate measurement of PGE2 is not
possible from in vivo samples, therefore the PGE2 metabolite
(PGEM) concentration is assessed in the serum and tumor lysate
of tumor-bearing mice.
PROTEOMICS
KCM and KCKO-tumor lysates from tumor-bearing mice were
electrophoretically separated, gel slices digested with trypsin and
analyzed using a Nano Acuity UPLC system connected to an LTQ-
Orbitrap hybrid MS system with a Nanospray interface. Data were
collected using Xcaliber and processed using Bioworks software
and mouse v.3.18 FASTA database. The following SEQUEST para-
meters were used: mass tolerance of 0.01 Da for precursor ions and
0.5 Da for fragment ions, variable modification on methionine of
16 Da, and maximum missed cleavage of 1. Search results were
entered into Scaffold software (Proteome Software; Portland, OR,
USA) for compilation, normalization, and comparison of spectral
counts. Protein identifications were made at the peptide proba-
bility of 95% and protein probability of 99%. Experiments for
Mass spectroscopy were duplicated for a power law global error
model (PLGEM). Datasets were imported into the R program for
statistical computing. Data are displayed as fold increase in KCM
cells/tumors as compared to KCKO cells/tumors.
STATISTICAL ANALYSES
All data are expressed as mean± SEM. Differences between con-
ditions tested were determined by one-way ANOVA followed by
Tukey’s post hoc test using GraphPad Prism 5.0 software (La
Jolla, CA, USA). The functional assays were analyzed by two-
way ANOVA followed by Bonferroni post-test using GraphPad
Prism 5.0 software. Probability values of p≤ 0.05 were considered
significant.
RESULTS
TDSFs FROMMUC1 EXPRESSING PDA CELLS FAVOR THE EXPANSION
OF MONOCYTIC MDSCs
Bone marrow cells were cultured in media supplemented with
GM-CSF and IL-4 with or without 30% v/v TCCM from KCM or
KCKO to determine whether MUC1 expression in PDA cells affects
MDSC expansion from BM cells. MUC1 expression was deter-
mined by western blotting using two antibodies, one to the MUC1
extracellular tandem repeat domain (MUC1 TR, >250 kDa) and
one to the cytoplasmic tail domain (MUC1 CT, <30 kDA). KCM
cells express high levels of MUC1 while KCKO, B16 (positive con-
trol), and 3T12 (negative control) cells do not (Figure 1A). On day
5 of BM culture, Gr1+CD11b+ cells were analyzed by flow cytom-
etry. With no TCCM (none) and FCM from 3T12 cells, ~30% of
the BM cells were Gr1+CD11b+ (Figure 1B) confirming previous
observations (24). BM cells cultured with B16 TCCM generated
>40% Gr1+CD11b+ cells also corroborating previous reports
(24). BM cells cultured with KCM TCCM and KCKO TCCM also
generated ~40% Gr1+CD11b+ cells. However, no difference was
noted in the Gr1+CD11b+ population between KCM and KCKO
TCCM (Figure 1B).
Next, we examined whether the presence of MUC1 in PDA
cells influences the differential expansion of the MDSC subsets,
i.e., monocytic versus granulocytic (24, 32). Cells were gated on
CD11b+ population and the two subset populations were ana-
lyzed based on presence/absence of Ly6G. A significant increase
in the monocytic subset (CD11b+Ly6G−Ly6C+, ~50 versus 35%,
p< 0.05) and a corresponding decrease in the granulocytic subset
(CD11b+Ly6G+Ly6C+, ~35 vs. ~45%, p< 0.01) was observed in
the BM cells treated with TCCM from KCM cells compared to
TCCM from KCKO cells (Figure 1C). Significantly, fewer mono-
cytic MDSCs were induced when BM cells were cultured with 3T12
FCM compared to TCCM from B16 or KCM cells (Figure 1C).
EXPRESSION OF MUC1 BY PDA CELLS HINDERS MDSC MATURATION
It is known that less mature MDSCs are more suppressive than
mature MDSCs (24, 33). Thus, we assessed the maturation state
of the MDSCs. An array of maturation and activation markers
including CD11c, CD115, CD80, CD86, F4/80, CD40, MHC class
I, MHC class II, B7H-1, and B7H-4 were analyzed. There was no
change in CD80, CD86, F4/80, CD40, MHC class I or II, B7H-1,
and B7H-4 levels (data not shown). However, we did observe a sig-
nificant upregulation in CD11c expression on the CD11b+ popu-
lation when BM cells were cultured in the presence of TCCM from
KCKO cells (Figure 2A) but not from KCM cells. CD11c (integrin
alpha X chain) is one of the markers of MDSC maturation and is
used to describe a subpopulation of mature MDSCs (34). Second,
we noted a significant down-regulation of CD115 expression on
the CD11b+ population when BM cells were cultured with TCCM
from KCM cells but not KCKO cells (Figure 2B). CD115 is a recep-
tor for colony-stimulating factor 1 (CSF-1) and is expressed on
monocytes, macrophages, and macrophage/dendritic cell precur-
sors and is a marker of mature myeloid cells (35). It is important
to note that of all the maturation and activation markers assessed,
a notable change was only observed in two markers. These mark-
ers are myeloid maturation markers while the others are myeloid
activation markers indicating that TCCM from KCKO cells may
promote maturation of MDSCs while TCCM from KCM cells
hinders its maturation.
EXPRESSION OF MUC1 IN PDA CELLS PROMOTES A SUPPRESSIVE
MDSC PHENOTYPE
We investigated whether the KCM-derived MDSCs were more
suppressive than the KCKO-derived MDSCs by evaluating the
expressions of iNOS and Arg-1 along with the concentrations
of their downstream byproducts, NO and urea, respectively. The
intracellular enzymes iNOS and Arg-1 are strongly associated with
MDSC-mediated suppression (4) and elevated levels of NO and
urea are produced by activated suppressive MDSCs (24). Sig-
nificant increases in the expression of iNOS+ and Arg-1+ cells
were observed within the KCM-derived versus KCKO-derived
Gr1+CD11b+ MDSC population (Figures 2C,D). To assess the
concentration of NO and urea, Gr1+ cells (MDSCs) were sorted
from BM cultures treated with TCCM or FCM and co-cultured
with varying ratios of activated splenocytes for 3 days. Signif-
icantly, higher concentrations of NO and urea were produced
by KCM-derived MDSCs as compared to KCKO-derived MDSCs
(Figure 2E).
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FIGURE 1 | Generation of MDSCs in the presence of variousTDSFs
in vitro. BM cells were harvested from 6- to 8-week C57BL/6 mice (n=4),
cultured for 5 days with GM-CSF, IL-4, and with or without 30% v/v
TCCM/FCM. Cells were stained with anti-Gr1, anti-CD11b, anti-Ly6C, and
anti-Ly6G antibodies and analyzed by flow cytometry. (A) Western blot
analysis and quantitative densitometry of the protein expressions of MUC1
probed with anti-MUC1 TR (detects extracellular motif of MUC1) and
anti-MUC1 CT (detects cytoplasmic tail motif of MUC1) antibodies on cell
lysates. MUC1 protein expression normalized to β-actin protein expression.
Western blotting for MUC1 and β-actin protein expression was carried out
three times; (B) Representative dot plot and graph of percent Gr1+CD11b+
cells; (C) Representative dot plot and graph of percent CD11b+Ly6C+LyG−
and CD11b+Ly6C+Ly6G+ cells. The MDSC subsets were obtained by gating
on CD11b+ cells as indicated (top left plot). Percentages are not absolute
numbers. Mean and standard error are plotted. *p<0.5, **p<0.01, and
***p<0.001 for statistically significant differences from control (3T12) levels
unless indicated by the line above the bars. A table of statistically significant
differences between each group is provided below dot plots.
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FIGURE 2 | Analysis of maturation and suppression markers on MDSCs
in response to variousTDSFs in vitro. BM cultures were established as
described (n=4 mice). Cells were stained with anti-Gr1, anti-CD11b,
anti-CD11c, anti-CD115, anti-iNOS, and anti-Arg-1 antibodies and analyzed by
flow cytometry. (A) CD11c expression on CD11b+ gated cells treated with
various TCCM; (B) CD115 expression on CD11b+ gated cells treated with
various TCCM. Results are expressed as mean fluorescence intensity (MFI)
along with representative histogram. Mean and standard error are plotted.
***p<0.001 for statistically significant differences from control (3T12) levels
and **p<0.01 for CD115 MFI differences between KCKO TCCM and KCM
TCCM; (C) Percent of iNOS+ cells on Gr1+CD11b+ gated cells treated with
various TCCM; (D) Percent of Arg-1+ cells on Gr1+CD11b+ gated cells treated
with various TCCM. Percentages are not absolute numbers; (E) Gr1+ cells
from BM cultures were co-cultured with freshly isolated splenocytes
stimulated with anti-CD3 for 3 days at ratios of 1:1, 1:2, and 1:4 for 72 h. The
nitric oxide concentration was assessed in the co-culture supernatant and the
urea concentration was assessed in the cell lysate. One representative
experiment out of three is shown. Mean and standard error are plotted.
*p< 0.05, **p<0.01, and ***p<0.001 for statistically significant differences
from control (L929) levels unless indicated by the line above the bars.
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KCM-TUMOR-BEARING MICE EXHIBIT HIGHER LEVELS OF MDSCs THAT
RETAIN THEIR IMMATURE STATE
To recapitulate the in vitro data in an in vivo setting, C57BL/6
mice were injected subcutaneously with 3T12, KCKO, and KCM
cells. At time of euthanasia (17 days post tumor challenge), tumors
were dissected and weighed. KCM-tumors were significantly larger
than the KCKO or 3T12 tumors (Figure 3A), matching previous
observations reported by our group (9).
Significantly, higher levels of Gr1+CD11b+ MDSCs were
observed in the spleen of KCM-tumor-bearing mice as compared
to KCKO or 3T12-tumor-bearing mice (Figure 3B). Although no
change in percent of MDSC was observed in the BM of KCM
versus KCKO-tumor-bearing mice (Figure 3C), the numbers of
monocytic and granulocytic populations were significantly higher
and lower, respectively, in the KCM compared to KCKO and 3T12-
tumor-bearing mice (Figures 3D,E) corroborating the in vitro data
(Figure 1C). Moreover, BM-derived MDSCs from KCM-tumor-
bearing mice had lower expression of CD11c and CD115 as com-
pared to MDSCs from KCKO-tumor-bearing mice (Figures 3F,G).
Thus, data clearly suggests that MDSCs from KCM-tumor-bearing
mice retain their immature state in vivo.
MDSCs FROM KCM-TUMOR-BEARING MICE ARE
IMMUNOSUPPRESSIVE
We assessed the expression of iNOS and Arg-1 on the MDSCs from
the BM of tumor-bearing mice. The percent of Gr1+CD11b+
MDSCs expressing iNOS and Arg-1 were significantly higher
in KCM as compared to KCKO and 3T12-tumor-bearing mice
(Figures 4A,B). Further, when BM-derived MDSCs from KCM-
tumor-bearing mice were co-cultured with varying ratios of acti-
vated splenocytes, higher concentrations of NO and urea were
produced (Figures 4C,D) at optimal co-culture ratios of 1:2 for
NO and 1:1 for urea. MDSCs from KCKO mice failed to pro-
duce NO or urea above basal levels (Figures 4C,D). In addition,
data shown in Figure 4E suggests that BM-derived MDSCs from
KCM-tumor-bearing mice may be capable of suppressing lympho-
cyte proliferation in a dose dependant manner to a greater extent
than BM-derived MDSCs from KCKO-tumor-bearing mice. For
this experiment, MDSCs had to be pooled from n= 3 mice due to
limited numbers of MDSCs obtained after sorting to conduct the
co-culture. Therefore, technical replicates were done and p-values
could not be generated using the two-way ANOVA statistical test.
However, a paired t -test between KCKO and KCM MFI values
was done for equivalent dilutions. The difference was found to be
significant (p≤ 0.05) at each dilution. A representative of three
experiments is shown in Figure 4E.
KCM CELLS EXPRESS SIGNIFICANTLY HIGHER LEVELS OF IL-10, COX-1,
AND 2, PGE SYNTHASE 2 AND 3, AND RELEASE HIGHER LEVELS OF PGE2
THAN KCKO CELLS
To determine the mechanism(s) underlying the MUC1 driven
generation of suppressive MDSCs, we assessed various immuno-
suppressive factors (TDSFs) implicated in MDSC generation. We
detected significantly higher levels of COX-2 and IL-10 by west-
ern blotting in KCM as compared to KCKO and L929 cell lysates
(Figure 5A). In Figure 5B, we confirm the presence and absence
of MUC1 by flow cytometry in KCM and KCKO from which
lysates were made and mice were injected with. In addition, the
proteomics data revealed significant fold increases in COX-1 (four-
fold), PGE synthase 2 (sevenfold), and PGE synthase-3 (threefold)
in KCM versus KCKO-tumors (Figure 5C). These enzymes are
involved in prostaglandin metabolism and are known to influence
MDSC generation, recruitment, and function in cancer.
Further, the concentration of PGE2, the major byproduct of
the COX enzyme activities was significantly higher in the KCM
TCCM compared to the KCKO and 3T12 TCCM (Figure 5D).
Similarly, levels of PGE metabolite (PGEM; 13,14-dihydro-15-keto
PGA2) were significantly higher in the tumors and serum of mice
bearing the KCM-tumor compared to KCKO and 3T12 tumors
(Figures 5E,F).
INHIBITION OF COX-2 REVERSES MUC1 DRIVEN EFFECTS ON MDSC
MATURATION AND FUNCTION
To determine if indeed MUC1 driven effects on MDSC mat-
uration and suppression were mediated by COX/PGE2, we
treated KCM cells with the selective inhibitor of COX-2 (Cele-
coxib). KCM cells were treated with 50µM of Celecoxib for
48 h and TCCM collected. Treatment with Celecoxib signifi-
cantly reduced the expression of COX-2 in KCM cells as deter-
mined by western blot analyses (Figure 6A). When BM cells
were cultured with TCCM from KCKO, KCM, and Celecoxib-
treated KCM cells, we observed no differences in the numbers
of total Gr1+CD11b+ cells (Figure 6B). However, a significant
increase was observed in the expression of the maturation mark-
ers (CD11c and CD115) in MDSCs derived using TCCM from
Celecoxib-treated KCM cells (Figures 6C,D). In addition, a signif-
icant decrease in the percentages of iNOS+ and Arg-1+ cells was
observed in MDSCs derived with TCCM from Celecoxib-treated
KCM cells, approaching the levels observed with KCKO TCCM
(Figures 6E,F). These findings strongly indicate that inhibit-
ing the COX-2 pathway enables the immature KCM-induced
MDSCs to undergo maturation and in turn lose their suppressive
phenotype.
DISCUSSION
Patients with pancreatic cancer display high levels of circulat-
ing tumor MUC1 (CA19-9) that correlate with poor prognosis
and disease recurrence (36). In addition, these patients exhibit
significant immune dysfunction characterized by increased lev-
els of immune suppressor cells including Tregs and MDSCs (37,
38). Although, tumor-associated MUC1 has been reported to be
immunosuppressive (39, 40), its role in MDSC generation and
function in pancreatic cancer has never been explored. We recently
reported that tumors from PDA mice that over express human
MUC1 have elevated levels of MDSCs and favor a highly immune
suppressive and pro-inflammatory microenvironment (13).
In this study, we report that there was a significant increase
in total MDSC numbers in the spleen of KCM versus KCKO-
tumor-bearing mice but no difference in the BM (Figure 3).
This implies that KCM-tumor may have a profound effect on the
recruitment of MDSCs to the lymphoid organs but not on its dif-
ferentiation in the BM. Further, we show in vitro that TCCM from
KCM cells promote the expansion of a monocytic MDSC subset,
that are immature and more suppressive than MDSCs derived
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FIGURE 3 | Characterization of MDSCs in tumor-bearing mice: C57BL/6
mice (n= 4) were injected in the flank with 1×106 3T12, KCM, and KCKO
cells. Upon sacrifice, the tumor, spleen, and bone marrow were harvested.
BM cultures were established as previously described. BMDCs were stained
with anti-Gr1, anti-CD11b, anti-Ly6C, anti-Ly6G, anti-CD11c, anti-CD115
antibodies, and analyzed as described previously. (A) Tumor wet weight in
grams; (B) Percentage of Gr1+CD11b+ cells in the spleen; (C) Percentage of
Gr1+CD11b+ cells in the bone marrow (D,E) Percentage of MDSC subsets
(CD11b+Ly6C+LyG− and CD11b+Ly6C+Ly6G+) in the bone marrow; (F,G)
CD11c and CD115 expression analyzed on CD11b+ gated cells from bone
marrow expressed in terms of MFI. Percentages are not absolute numbers.
Mean and standard error are plotted. *p<0.05, **p<0.01, and ***p<0.001
for statistically significant differences from control (3T12) levels unless
indicated by line above the bars.
using TCCM from KCKO cells (Figure 1). Interestingly, when
the individual MDSC subsets were further analyzed for presence
of maturation and suppressive markers, lower levels of CD11c
and CD115 was observed in both the monocytic and granulo-
cytic MDSC subsets (Figures S1C–F in Supplementary Material).
However, an increase in iNOS+ cells was predominantly in the
monocytic subset while an increase in Arg-1+ cells was predom-
inantly in the granulocytic subset (Figures S1G–J in Supplemen-
tary Material). The observations that the suppressive activity of
MDSCs is primarily conferred by the monocytic subset and that
as MDSCs mature, they lose their suppressive capability is sup-
ported by several other published studies (24, 32, 33). Our findings
indicate that MUC1 expression in the tumor plays a key role
in maintaining the MDSCs in an immature and highly suppres-
sive state and may partially account for the metastatic nature of
MUC1+ PDA tumors. Indeed, KCM-tumors grow significantly
larger than KCKO-tumors in immune competent syngeneic mice
(9, 13) (Figure 3A).
Both COX-2 and IL-10 are implicated in MDSC expansion and
activation (15). It is well established that there is a positive feed-
back between PGE2 and COX-2 that redirects the differentiation
of human dendritic cells toward stable MDSCs (41, 42). In line
with that, our data demonstrates that KCM cells express high lev-
els of COX-2 and IL-10 (Figure 5A) and stimulates the generation
of highly suppressive and immature MDSCs, thus highlighting
the clinical significance of the study. Furthermore, compared
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FIGURE 4 | Analysis of suppressive markers on MDSCs in
tumor-bearing mice: C57BL/6 mice (n=4) were injected in the flank
with 1×106 3T12, KCM, and KCKO cells. BM cultures were established
as previously described. BMDCs were stained with anti-CD11b, anti-iNOS,
and anti-Arg-1 antibodies and analyzed as described previously.
(A,B) Percentages iNOS+ and Arg-1+ cells on Gr1+CD11b+ BM gated cells.
Percentages are not absolute numbers; Splenocytes were isolated from
naïve C57BL/6 mice and co-cultured at 1:1 ratio with Gr1+ cells isolated
from BM cultures from tumor-bearing mice for NO and urea production
analyses. (C,D) Concentrations of NO and urea were assessed in the
supernant and cell lysate respectively of freshly isolated splenocytes
stimulated for 3 days with anti-CD3 in the presence or absence of sorted
Gr1+ cells from BM cultures of tumor-bearing mice. Mean and standard
error are plotted. For (A,B) *p<0.05, **p<0.01, and ***p< 0.001 for
statistically significant differences from control (3T12) levels unless
indicated by line above the bars; (E) CFSE labeled splenic cells were
stimulated for 3 days with anti-CD3 in the presence or absence of sorted
Gr1+ cells at varying ratios from BM cultures of tumor-bearing mice to
assess lymphocyte proliferation. Data is expressed in terms of proliferation
index (all CSFE MFI were normalized to Day 0 CFSE fluorescence of
splenocytes). Data is representative of one of three experiments. Due to
technical issues, there were no biological replicates for this experiment and
hence a two-way ANOVA could not be performed. However, a paired t-test
was conducted between KCKO and KCM MFI values for equivalent
dilutions. The difference was found to be significant (p≤0.05) at each
dilution (not shown).
to KCKO, KCM-tumors exhibit a fourfold increase in COX-1,
sevenfold increase in PGE synthase-2, and threefold increase in
PGE synthase-3 levels (Figure 5C). Thus, we postulate that KCM
cells may activate the COX-pathway which in turn contributes
to the generation of suppressive MDSCs. These increases in the
COX-pathway enzymes were correlated with elevated levels of
PGE2 in the TCCM from KCM-tumor cells and PGEM (PGE2
metabolite) in the tumor and serum of KCM-tumor-bearing mice
(Figures 5D–F). Thus, when TCCM from celecoxib-treated KCM
cells was used, the MDSCs generated expressed low suppressive
factors and high maturation markers similar to the phenotype
generated with KCKO TCCM (Figures 6C–F). The PGE synthases
along with COX-1 and COX-2 are essential for the synthesis of
prostaglandins including PGE2 from Prostaglandin H2 and are
being explored as novel therapeutic targets for treatment of vari-
ous inflammatory diseases and cancer (43, 44). The central role
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FIGURE 5 | Analysis ofTDSFs from KCM and KCKO cells involved in
MDSC-mediated suppression. Whole cell lysate, conditioned media, tumor
lysate, and serum were analyzed for common immune modulating factors.
(A) Whole cell lysates (30µg) of KCM and KCKO cells were loaded onto SDS
gels and blotted with anti-COX-2, anti-IL-10, and anti-β-actin. The quantitative
densitometry of the protein expressions of COX-2 and IL-10 normalized to
β-actin is shown as well. Western blotting for COX-2, IL-10, and β-actin protein
expression was carried out three times; (B) MUC1 expression in KCKO and
KCM cells determined by flow cytometry. The gate for percentage positive
MUC1 cells was set using the appropriate isotype control; (C) Proteins
over-expressed in KCM versus KCKO-tumor cell lysates from tumor-bearing
mice determined by proteomics analyses (Data expressed in fold changes);
(D) PGE2 concentrations in conditioned media of KCM and KCKO cells
measured by ELISA; (E,F) PGEM (13,14-dihydro-15-keto PGA2) concentrations
quantified by ELISA in serum and tumor lysate from tumor-bearing mice
(n=4). Mean and standard error plotted. *p<0.05, **p<0.01, and
***p<0.001 for statistically significant differences from control levels unless
indicated by the line above the bars.
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FIGURE 6 | COX-2 inhibitor Celecoxib reverses the suppressive
phenotype of MDSCs. BM cells (n=4) were cultured with 30% v/v
TCCM from KCKO, KCM, and celecoxib-treated KCM cells (with 50µM
Celecoxib). Cells were stained with anti-Gr1, anti-CD11b, anti-CD11c,
anti-CD115, anti-iNOS, and anti-Arg-1 antibodies. (A) Western blot
analysis and quantitative densitometry of the protein expression of
COX-2 gene on whole cell lysates from KCM and celecoxib-treated KCM
cells. COX-2 protein expression was normalized for β-actin protein
expression. Western blotting for COX-2 and β-actin protein expression
was carried out 3 times; (B) Percentage of Gr1+CD11b+ MDSC
population; (C,D) Expression of CD11c and CD115 expression on
Gr1+CD11b+ cells; (E,F) Percentage of iNOS+ and Arg-1+ cells on
Gr1+CD11b+ gated cells. Percentages are not absolute numbers. Mean
and standard error are shown. *p<0.05, **p< 0.01, and ***p<0.001
for statistically significant differences from KCKO levels unless indicated
by the line above the bars.
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of COX-2-PGE2 feedback in the induction and persistence of
MDSCs highlights the potential for its manipulation to enhance
or suppress immune responses in cancer (41, 42).
Taken together, the data suggests that tumor-associated MUC1
in KCM cells hinders myeloid maturation and drives the gen-
eration and maintenance of an immature, suppressive MDSC
population partly via activation of the COX-pathway. [Of note
is that the two cell lines KCM and KCKO are derived from the same
triple transgenic PDA mouse model that expresses the KRASG12D
mutation driven by the P48 promoter and are therefore geneti-
cally similar (12) except for the presence or absence of Muc1
(9, 13)].
One of the limitations of this study is that all experiments were
conducted using KCM and KCKO cell lines. We were unable to
conduct these experiments with other cells because there are no
other PDA cell lines that are derived in a Muc1-null background.
Although there are other low and high MUC1 expressing cells,
none that we know lack MUC1 message completely. Since in vivo
experiments had to be conducted in immune competent mice,
human cell lines could not be used for this study. Nevertheless, to
confirm that the effect on MDSC may be regulated by the absence
or presence of MUC1, we did conduct some of the same exper-
iments using a melanoma cell line (B16) that completely lacks
MUC1 message and protein and is syngeneic for C57/BL6 mice
thus avoiding strain-related differences. The B16 cells were sta-
bly transfected with full-length human MUC1 (designated B16
MUC1) or empty vector (B16 Neo). Figure S2A in Supplemen-
tary Material illustrates high MUC1 expression in B16 MUC1
with undetectable levels in B16 Neo cells. MDSCs were isolated
from the BM of B16 MUC1 and B16 Neo-tumor-bearing mice
and compared to MDSCs isolated from KCM and KCKO-tumor-
bearing mice. Results recapitulate the data observed with KCM
and KCKO. First, we observed no significant difference in the total
numbers of MDSCs between B16 Neo and B16 MUC1 tumor-
bearing mice. Second, significantly higher numbers of monocytic
MDSCs and lower numbers of granulocytic MDSCs was detected
in B16 MUC1 versus B16 Neo-tumor-bearing mice (Figures S2B–
D in Supplementary Material). Finally, compared to MDSCs from
B16 Neo-tumor-bearing mice, MDSCs from B16 MUC1 mice
expressed significantly higher levels of iNOS (Figures S2E–G in
Supplementary Material) and Arg-1 (Figures S2H–J in Supple-
mentary Material). These data confirm that the effect on MDSC
maturation and function may be regulated by the absence or
presence of MUC1.
The effect of COX-2 inhibition on MDSC function is not sur-
prising as this has been established with other tumor types (45).
Our observations indicate that KCM cells express higher levels
of COX-2 and secrete higher levels of PGE2 than KCKO cells
(Figures 5A,D–F). Thus, we hypothesize that the induction of the
highly suppressive and immature MDSCs induced by KCM cells
may be via the up regulation of the COX-pathways and synthesis
of PGE2. Our upcoming studies will further our understanding
of the underlying mechanisms by which the MUC1 glycoprotein
regulates the COX-2 pathway in PDA and examine the effects of
shed MUC1 on MDSC maturation and function.
In human PDA, MUC1, and COX-2/PGE2 pathways are highly
activated and patients have high levels of MDSCs in the tumor,
spleen, and blood, thus our data has high clinical relevance as
future therapies can be designed to target MUC1 and COX-2
signaling. Targeting MDSCs along with a cancer antigen greatly
improves the efficacy of the cancer vaccine (46, 47) and in this
regard, we have previously reported that simultaneous targeting
of MUC1 and COX-2 in a spontaneous model of PDA was highly
effective in stalling the progression of PanIN lesions to adenocarci-
nomas and in inhibiting invasive disease (48). Data from this study
furthers our understanding of the mechanisms by which the com-
bination treatment was effective and provides further rationale
for designing clinical trials targeting MUC1 and COX signaling
pathways to overcome cancer mediated immune suppression.
Clearly, for the present study to have clinical relevance, these
findings have to be validated using patient samples. We have
recently published that MUC1 was detected in the circulation
of pancreatic cancer patients in a stage-dependent manner (49).
Future studies will focus on determining levels of MDSCs and
T-regulatory cells in patients with MUC1+ and MUC1− PDA.
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